HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Chronic proliferative enteritis of intestine — Clinical Guidelines

Overview

Chronic proliferative enteritis of the intestine, often associated with conditions like chronic inflammatory bowel disease (IBD), particularly ulcerative colitis, is characterized by persistent inflammation and abnormal tissue proliferation within the intestinal mucosa. This condition significantly impacts gastrointestinal function, leading to symptoms such as abdominal pain, diarrhea, and malabsorption. It predominantly affects individuals with a history of chronic inflammatory processes, potentially exacerbating quality of life and increasing the risk of complications like strictures and neoplasia. Understanding and managing this condition is crucial in day-to-day practice to prevent disease progression and improve patient outcomes 1 3.

Pathophysiology

Chronic proliferative enteritis arises from a complex interplay of inflammatory mediators and cellular responses within the intestinal mucosa. The initial trigger often involves chronic inflammation driven by pro-inflammatory cytokines such as TNF-α, IL-1α, IL-6, and IFN-γ, which are hallmarks of conditions like ulcerative colitis 2 3. These cytokines disrupt the normal balance of epithelial cell proliferation and differentiation, leading to excessive cell turnover and impaired barrier function. The persistent inflammation stimulates crypt cell proliferation as a compensatory mechanism to regenerate damaged tissue, but this process can become dysregulated, contributing to the proliferative phenotype observed in chronic enteritis 3. Additionally, the involvement of growth factors like R-spondin1 highlights a potential therapeutic avenue; R-spondin1 stimulates mucosal regeneration and reduces inflammation, suggesting that modulating these pathways could mitigate disease progression 3.

Epidemiology

The exact incidence and prevalence of chronic proliferative enteritis as a distinct entity are not well-documented, but it is closely linked to chronic IBD, which affects approximately 0.5% to 1% of the population globally 3. Prevalence tends to be higher in younger adults, with a peak incidence in individuals aged 15 to 35 years, though it can occur at any age. Geographic variations exist, with higher rates observed in industrialized regions, possibly due to environmental and lifestyle factors. Risk factors include genetic predisposition, smoking, and certain dietary habits. Over time, there has been a trend towards earlier diagnosis and increased awareness, potentially influencing reported prevalence rates 3.

Clinical Presentation

Patients with chronic proliferative enteritis typically present with a constellation of gastrointestinal symptoms including chronic diarrhea, abdominal pain, and weight loss. Atypical presentations may include extraintestinal manifestations such as arthritis, skin lesions, and ocular inflammation, reflecting the systemic nature of chronic inflammation. Red-flag features include severe anemia, persistent fever, and signs of bowel obstruction, which necessitate urgent evaluation to rule out complications like strictures or toxic megacolon. Accurate clinical assessment is crucial for timely diagnosis and intervention 1 3.

Diagnosis

The diagnostic approach for chronic proliferative enteritis involves a combination of clinical evaluation, endoscopic findings, and histopathological analysis. Key diagnostic criteria include:

Clinical Symptoms: Chronic diarrhea, abdominal pain, weight loss 3.

Endoscopic Features: Continuous or discontinuous areas of mucosal inflammation, friability, and ulcerations in the colon 3.

Histopathological Findings: Crypt architectural distortion, basal plasmacytosis, and crypt abscesses on biopsy samples 3.

Laboratory Tests: Elevated inflammatory markers (e.g., CRP, ESR), anemia, and fecal calprotectin levels 3.

Differential Diagnosis:

- Irritable Bowel Syndrome (IBS): Typically lacks endoscopic and histological abnormalities 3. - Microscopic Colitis: Characterized by normal endoscopic appearance but abnormal histology 3. - Infectious Colitis: Often associated with specific pathogens and a more acute onset 3.

Management

First-Line Treatment

Anti-inflammatory Agents:

- 5-Aminosalicylates (5-ASA): Oral mesalamine 2.4-4.8 g/day 3. - Corticosteroids: Prednisolone 40-60 mg/day for short-term use 3.

Immunomodulators:

- Azathioprine: 1-2 mg/kg/day 3. - 6-Mercaptopurine (6-MP): 1-2 mg/kg/day 3.

Monitoring: Regular assessment of inflammatory markers, clinical symptoms, and side effects 3.

Second-Line Treatment

Biologics:

- Anti-TNF Agents: Infliximab 5 mg/kg intravenously every 6-8 weeks 3. - Integrin Antagonists: Vedolizumab 300 mg intravenously every 8 weeks 3.

Targeted Therapy:

- JAK Inhibitors: Tofacitinib 10-15 mg twice daily (off-label use) 3.

Monitoring: Close monitoring for infections, malignancies, and drug efficacy 3.

Refractory or Specialist Escalation

Combination Therapy: Integrating multiple agents as above 3.

Surgical Intervention: Consideration for refractory cases with complications like toxic megacolon or strictures 3.

Specialist Referral: Gastroenterology or IBD specialist for tailored management plans 3.

Complications

Strictures: Development of intestinal strictures requiring endoscopic dilation or surgical intervention 3.

Neoplasia: Increased risk of colorectal cancer, necessitating regular surveillance colonoscopies 3.

Malnutrition: Chronic diarrhea leading to nutritional deficiencies, requiring supplementation 3.

When to Refer: Persistent symptoms despite medical therapy, suspicion of complications, or need for advanced diagnostic procedures 3.

Prognosis & Follow-Up

The prognosis for chronic proliferative enteritis varies widely depending on disease severity and response to treatment. Prognostic indicators include the extent of mucosal damage, presence of complications, and patient adherence to therapy. Recommended follow-up intervals typically include:

Clinical Assessment: Every 3-6 months initially, then annually if stable 3.

Endoscopic Surveillance: Every 1-2 years, particularly in patients with long-standing disease 3.

Colonoscopy with Biopsy: Every 1-3 years to monitor for dysplasia or cancer 3.

Special Populations

Pregnancy: Management focuses on minimizing disease activity while avoiding teratogenic drugs; 5-ASA is generally considered safe 3.

Pediatrics: Early diagnosis and tailored therapy are crucial; immunomodulators and biologics are used cautiously due to long-term safety concerns 3.

Elderly: Increased risk of side effects from medications; careful monitoring and dose adjustments are necessary 3.

Comorbidities: Patients with comorbidities like cardiovascular disease require careful consideration of drug interactions and side effects 3.

Key Recommendations

Initiate 5-ASA Therapy for mild to moderate disease; monitor response and adjust as needed (Evidence: Strong) 3.

Consider Corticosteroids for acute flares; limit use to short durations to avoid long-term side effects (Evidence: Moderate) 3.

Use Immunomodulators (azathioprine, 6-MP) for maintenance therapy in moderate to severe cases (Evidence: Strong) 3.

Evaluate and Initiate Biologic Therapy for patients refractory to conventional treatments (Evidence: Moderate) 3.

Regular Surveillance Colonoscopies every 1-3 years for patients with longstanding disease to monitor for dysplasia (Evidence: Moderate) 3.

Monitor Inflammatory Markers (CRP, ESR, fecal calprotectin) regularly to assess disease activity (Evidence: Moderate) 3.

Consider JAK Inhibitors as an alternative in patients intolerant to biologics (Evidence: Weak) 3.

Refer to IBD Specialist for complex cases or refractory disease (Evidence: Expert opinion) 3.

Implement Nutritional Support for patients with significant malnutrition (Evidence: Moderate) 3.

Tailor Management in Special Populations considering age, pregnancy status, and comorbidities (Evidence: Expert opinion) 3.

References

1 Andújar I, Ríos JL, Giner RM, Recio MC. Shikonin promotes intestinal wound healing in vitro via induction of TGF-β release in IEC-18 cells. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2013. link 2 Adler UC. Low-grade inflammation in chronic diseases: an integrative pathophysiology anticipated by homeopathy?. Medical hypotheses 2011. link 3 Zhao J, de Vera J, Narushima S, Beck EX, Palencia S, Shinkawa P et al.. R-spondin1, a novel intestinotrophic mitogen, ameliorates experimental colitis in mice. Gastroenterology 2007. link 4 Martinsson T. Ropivacaine inhibits serum-induced proliferation of colon adenocarcinoma cells in vitro. The Journal of pharmacology and experimental therapeutics 1999. link 5 Kähler CM, Herold M, Reinisch N, Wiedermann CJ. Interaction of substance P with epidermal growth factor and fibroblast growth factor in cyclooxygenase-dependent proliferation of human skin fibroblasts. Journal of cellular physiology 1996. link1097-4652(199603)166:3<601::AID-JCP15>3.0.CO;2-9) 6 Kähler CM, Herold M, Wiedermann CJ. Substance P: a competence factor for human fibroblast proliferation that induces the release of growth-regulatory arachidonic acid metabolites. Journal of cellular physiology 1993. link

Chronic proliferative enteritis of intestine